TITAN PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.7 USD | -0.07% |
|
-3.87% | -18.79% |
| Apr. 01 | Titan Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Jan. 26 | Titan Pharmaceuticals Regains Compliance With Nasdaq Listing Rule | MT |
Financials (USD)
| Sales 2022 | 557K | Sales 2023 | 184K | Capitalization | 6.21M |
|---|---|---|---|---|---|
| Net income 2022 | -10M | Net income 2023 | -5M | EV / Sales 2022 | 15.6 x |
| Net cash position 2022 | 2.75M | Net cash position 2023 | 6.2M | EV / Sales 2023 | 0.11 x |
| P/E ratio 2022 |
-1.03
x | P/E ratio 2023 |
-1.11
x | Employees | 4 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 54.53% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -0.07% | ||
| 1 week | -3.87% | ||
| Current month | -0.07% | ||
| 1 month | -6.69% | ||
| 3 months | +3.88% | ||
| 6 months | -22.09% | ||
| Current year | -18.79% |
1 week
6.60
7.00
1 month
6.609.07
Current year
5.259.35
1 year
5.0016.60
3 years
5.0062.00
5 years
5.001 176.00
10 years
5.0036 000.05
| Members of the board | Title | Age | Since |
|---|---|---|---|
Avraham Ben-Tzvi
BRD | Director/Board Member | 53 | 22-08-14 |
Gim Shen Seow
CEO | Chief Executive Officer | 42 | 23-10-11 |
Brynner Chiam
BRD | Director/Board Member | - | 23-10-11 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-01 | 6.7 | -0.07% | 2,029 |
| 24-04-30 | 6.705 | -2.12% | 3,307 |
| 24-04-29 | 6.85 | -3.39% | 2,706 |
| 24-04-26 | 7.09 | +1.72% | 10,649 |
| 24-04-24 | 6.97 | -0.57% | 2,582 |
Delayed Quote Nasdaq, May 01, 2024 at 04:30 pm EDT
More quotes
Titan Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. ProNeura offers continuous drug delivery and consists of a small, semi-rigid, flexible implant made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The resulting product is a solid matrix implant that is placed subdermally, normally in the inside part of the upper arm, in a brief procedure using a local anesthetic and is removed in a similar manner at the end of the treatment period. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus. Its product development programs are in non-clinical stages of development.
Sector
Pharmaceuticals
Calendar
2024-11-10
- Q3 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -18.79% | 6.13M | |
| +29.68% | 681B | |
| +21.42% | 556B | |
| -4.35% | 361B | |
| +17.65% | 325B | |
| +3.77% | 285B | |
| +13.58% | 235B | |
| +4.55% | 199B | |
| -12.39% | 189B | |
| -3.79% | 157B |
- Stock Market
- Equities
- TTNP Stock
